Fidelity Investments
FDMT icon

Fidelity Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

Fidelity Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
128,316
+58,219
+83% +$567K ﹤0.01% 2810
2026
Q1 		$653K Buy
70,097
+4,448
+7% +$38.7K ﹤0.01% 3017
2025
Q4 		$492K Buy
65,649
+79
+0.1% +$801 ﹤0.01% 3090
2025
Q3 		$570K Buy
65,570
+3,504
+6% +$20.9K ﹤0.01% 2985
2025
Q2 		$230K Buy
62,066
+54,200
+689% +$191K ﹤0.01% 3257
2025
Q1 		$25.4K Buy
7,866
+5,824
+285% +$27.4K ﹤0.01% 4134
2024
Q4 		$11.4K Sell
2,042
-2,058
-50% -$16.1K ﹤0.01% 4424
2024
Q3 		$44.3K Sell
4,100
-1,012,123
-100% -$16.8M ﹤0.01% 3830
2024
Q2 		$21.3M Buy
1,016,223
+47,341
+5% +$1.19M ﹤0.01% 1622
2024
Q1 		$30.9M Buy
968,882
+965,245
+26,540% +$24.6M ﹤0.01% 1508
2023
Q4 		$73.7K Buy
3,637
+881
+32% +$11.6K ﹤0.01% 3345
2023
Q3 		$35.1K Sell
2,756
-76
-3% -$1.27K ﹤0.01% 3523
2023
Q2 		$51.2K Buy
2,832
+138
+5% +$2.54K ﹤0.01% 3418
2023
Q1 		$46.3K Sell
2,694
-24,208
-90% -$471K ﹤0.01% 3483
2022
Q4 		$597K Sell
26,902
-261,302
-91% -$4.04M ﹤0.01% 2665
2022
Q3 		$2.32M Sell
288,204
-412,248
-59% -$3.73M ﹤0.01% 2395
2022
Q2 		$4.89M Sell
700,452
-390,766
-36% -$3.8M ﹤0.01% 2244
2022
Q1 		$16.5M Sell
1,091,218
-48,957
-4% -$769K ﹤0.01% 1873
2021
Q4 		$25M Buy
1,140,175
+118,202
+12% +$2.9M ﹤0.01% 1720
2021
Q3 		$27.6M Sell
1,021,973
-15,753
-2% -$449K ﹤0.01% 1681
2021
Q2 		$25M Sell
1,037,726
-249,845
-19% -$7.65M ﹤0.01% 1744
2021
Q1 		$55.9M Sell
1,287,571
-306,784
-19% -$13.6M ﹤0.01% 1348
2020
Q4 		$66.1M Buy
+1,594,355
New +$65.8M 0.01% 1210

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Fidelity Investments's FDMT Position: Q2 2026 in Review

Fidelity Investments increased its 4D Molecular Therapeutics (FDMT) stake by 83% in Q2 2026, buying an estimated $567K and bringing the position to 128,316 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2810.

Fidelity Investments first reported a position in FDMT in Q4 2020 and has held it in 23 quarters since. The position peaked at $66.1M in Q4 2020. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Fidelity Investments held 128,316 shares of 4D Molecular Therapeutics worth $1.71M as of Q2 2026.
  • Fidelity Investments bought 58,219 4D Molecular Therapeutics shares in Q2 2026, an estimated $567K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2810 holding.
  • Fidelity Investments first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Fidelity Investments's 4D Molecular Therapeutics position peaked at $66.1M in Q4 2020.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.